机构:[1]Department of Oncology, the First affiliated Hospital of Guangdong Pharmaceutical University, Guangdong 510080, People’s Republic of China[2]State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, Guangdong 510060, People’s Republic of China其他部门华南肿瘤学国家重点实验室中山大学肿瘤防治中心[3]Department of Radiation Oncology, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong 510060, People’s Republic of China临床科室放疗科中山大学肿瘤防治中心[4]Department of Radiation Oncology, First Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong 510060, People’s Republic of China其他科室肿瘤科中山大学附属第一医院[5]Department of Hematologic Oncology, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong 5100600, People’s Republic of China临床科室血液肿瘤科中山大学肿瘤防治中心[6]Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong 510060, People’s Republic of China临床科室内科中山大学肿瘤防治中心
This study retrospectively investigated asparaginase-based chemotherapy treatment outcomes with or without radiotherapy in 143 patients with stage I-E-IIE extranodal natural killer/T cell lymphoma (ENKTCL). All patients received a median of three cycles of asparaginase-based chemotherapy, while 121 patients received radiotherapy following the chemotherapy. The complete remission (CR) rate for all patients post-chemotherapy was 58.7%, and rose to 73.4% by the end of treatment. Patients who received radiotherapy achieved better survival outcomes than those who did not (89.7% vs. 49.0% for 2-year overall survival (OS), P<0.001; 86.8% vs. 37.4% for 2-year progression-free survival (PFS),P<0.001). Additionally, even patients who achieved CR post-chemotherapy exhibited differential survival rates with or without radiotherapy (90.8% vs. 60% for 2-year OS, P=0.006; 86.1% vs. 60% for 2-year PFS, P=0.044). Multivariate analysis revealed that radiotherapy was an independent factor favoring OS (HR=0.098, 95% CI=0.031-0.314, P=0.001) and PFS (HR=0.156, 95% CI=0.062-0.396, P=0.001). Thus, radiotherapy is recommended for stage IE-IIE ENKTCL patients treated with asparaginase-based chemotherapy, even in cases of CR following chemotherapy.
语种:
外文
被引次数:
WOS:
PubmedID:
中科院(CAS)分区:
出版当年[2017]版:
大类|2 区医学
小类|2 区肿瘤学3 区细胞生物学
最新[2023]版:
无
第一作者:
第一作者机构:[1]Department of Oncology, the First affiliated Hospital of Guangdong Pharmaceutical University, Guangdong 510080, People’s Republic of China[2]State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, Guangdong 510060, People’s Republic of China[3]Department of Radiation Oncology, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong 510060, People’s Republic of China
共同第一作者:
通讯作者:
通讯机构:[1]Department of Oncology, the First affiliated Hospital of Guangdong Pharmaceutical University, Guangdong 510080, People’s Republic of China[2]State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, Guangdong 510060, People’s Republic of China[3]Department of Radiation Oncology, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong 510060, People’s Republic of China
推荐引用方式(GB/T 7714):
Yi-Yang Li,Ling-Ling Feng,Shao-Qing Niu,et al.Radiotherapy improves survival in early stage extranodal natural killer/T cell lymphoma patients receiving asparaginase-based chemotherapy[J].ONCOTARGET.2017,8(7):11480-11488.doi:10.18632/oncotarget.14006.